Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426197 | 0.86 | EPHX2 (0.46) | HTR6HTTLMNAKMT2ARXFP1 | |
| SCHEMBL5781943 | 0.86 | HTR6 (0.50) | HTR6ALDH1A1HTT | |
| SCHEMBL5427129 | 0.85 | LMNA (0.59) | SMN1; SMN2ALDH1A1L3MBTL1HTTLMNA | |
| SCHEMBL5432653 | 0.82 | TSHR (0.54) | SMN1; SMN2ALDH1A1L3MBTL1HTTLMNA | |
| SCHEMBL3155760 | 0.82 | HTR6 (0.63) | HTR6 | |
| SCHEMBL5783205 | 0.82 | HTR6 (0.42) | HTR6SMN1; SMN2ALDH1A1L3MBTL1HTT | |
| SCHEMBL5428107 | 0.81 | HTR6 (0.47) | HTR6ALDH1A1L3MBTL1TP53 | |
| SCHEMBL5426162 | 0.81 | HTR6 (0.45) | HTR6ALDH1A1L3MBTL1HTTLMNA | |
| SCHEMBL5785930 | 0.80 | PKM (0.41) | HTR6ALDH1A1LMNAPOLBRXFP1 | |
| SCHEMBL5426366 | 0.80 | HTR6 (0.47) | HTR6ALDH1A1LMNARXFP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | claimed |
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032482-A1 | Benzoxazinone-derived sulfonamide compounds, their preparation and use as medicaments | HTR6, HTR5A, P2RX6 | HTR6 1/4885SMN1; SMN2 4172/4885ALDH1A1 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.